Observational study / 2013
Elevated plasma vitamin B12 levels were linked to an increased risk of subsequently diagnosed cancer, especially during the first year of follow-up.
Researchers analyzed 333,667 Danish patients referred for cobalamin (Cbl) measurement without prevalent cancer or Cbl treatment (1998-2009) to assess cancer incidence. Six percent had Cbl levels ≥601 pmol/L. Cancer risk increased with higher Cbl levels and peaked during the first year of follow-up (Cbl 601-800 pmol/L: SIR = 3.44, 95% CI = 3.14 to 3.76; Cbl >800 pmol/L: SIR = 6.27, 95% CI = 5.70 to 6.88; both P < .001). Elevated risks were particularly notable for hematological and smoking- and alcohol-related cancers.
Shows an association, not proof of cause and effect.
- Study type
- Population-based cohort study
- Who was studied
- 333,667 persons in Northern Denmark referred for Cbl measurement, without prevalent cancer and not receiving Cbl treatment
- What was measured
- Cancer risk (standardized incidence ratios [SIRs]) by plasma vitamin B12 (cobalamin) levels
THE PAPER
Elevated plasma vitamin B12 levels as a marker for cancer: a population-based cohort study.
Arendt JF, Pedersen L, Nexo E, Sørensen HT. J Natl Cancer Inst, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.